Contribution of Impaired Insulin Signaling to the Pathogenesis of Diabetic Cardiomyopathy

Otros/as autores/as

Institut Català de la Salut

[Zamora M] BCNatal, Fetal Medicine Research Center, Barcelona, Spain. Hospital Clínic, Barcelona, Spain. Hospital Sant Joan de Déu, Barcelona, Spain. Universat de Barcelona, Barcelona, Spain. Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. [Villena JA] Laboratori de Metabolisme i Obesitat, Vall d’Hebron Institut de Recerca, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. CIBERDEM, CIBER on Diabetes and Associated Metabolic Diseases, Instituto de Salud Carlos III, Madrid, Spain

Vall d'Hebron Barcelona Hospital Campus

Fecha de publicación

2019-07-19T08:38:54Z

2019-07-19T08:38:54Z

2019-06-11



Resumen

Diabetes; Diabetic cardiomyopathy; Heart


Diabetis; Cardiomiopatia diabètica; Cor


Diabetes; Cardiomiopatía diabética; Corazón


Diabetic cardiomyopathy (DCM) has emerged as a relevant cause of heart failure among the diabetic population. Defined as a cardiac dysfunction that develops in diabetic patients independently of other major cardiovascular risks factors, such as high blood pressure and coronary artery disease, the underlying cause of DCMremains to be unveiled. Several pathogenic factors, including glucose and lipid toxicity, mitochondrial dysfunction, increased oxidative stress, sustained activation of the renin-angiotensin system (RAS) or altered calcium homeostasis, have been shown to contribute to the structural and functional alterations that characterize diabetic hearts. However, all these pathogenic mechanisms appear to stem from the metabolic inflexibility imposed by insulin resistance or lack of insulin signaling. This results in absolute reliance on fatty acids for the synthesis of ATP and impairment of glucose oxidation. Glucose is then rerouted to other metabolic pathways, with harmful effects on cardiomyocyte function. Here, we discuss the role that impaired cardiac insulin signaling in diabetic or insulin-resistant individuals plays in the onset and progression of DCM.


Supported by grants BFU2015-64462R from the Ministerio de Economía y Competitividad (MINECO/FEDER, UE) and HR17-00627 from La Caixa Foundation to J.A.V.

Tipo de documento

Artículo


Versión publicada

Lengua

Inglés

Publicado por

MDPI

Documentos relacionados

International Journal of Molecular Sciences;20(11)

https://www.mdpi.com/1422-0067/20/11/2833

Citación recomendada

Esta citación se ha generado automáticamente.

Derechos

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

Este ítem aparece en la(s) siguiente(s) colección(ones)